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To the Editor, 
 
Hypercholesterolemia continues to be an important comorbidity often seen in heart transplant (HT) 
recipients and is associated with a higher cardiovascular risk and with the appearance of graft vascular 
disease (GVD).1 Statin therapy in this patient group has been shown to significantly reduce the incidence 
of acute graft rejection and GVD and to increase survival, benefits attributable not only to lower plasma 
cholesterol concentrations but also to the immunomodulatory effects of statins.2 Consequently, clinical 
practice guidelines recommend long-term use in all HT recipients, regardless of low-density lipoprotein 
cholesterol (LDL-C) levels.3 
 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) selectively binds to LDL-C receptors in the 
hepatocyte membrane, enhancing receptor breakdown and indirectly raising plasma LDL-C 
concentrations. The PCSK9 inhibitors (PCSK9i) known as alirocumab and evolocumab are monoclonal 
antibodies that block the activity of this protein, and they have been shown to significantly reduce LDL-C 
and the risk of cardiovascular events.4 Furthermore, PCSK9 metabolism does not involve cytochrome 
P450 or certain hepatic carriers, such as organic anion transporting polypeptide C (OATP-C), which play 
a key role in the process that breaks down statins and common immunosuppressant drugs, thereby 
dramatically reducing the likelihood of drug interactions and adverse reactions. Hence, this 
pharmacological group is an interesting therapeutic alternative for the treatment of hypercholesterolemia 
in HT recipients, although there is currently little evidence on its safety and efficacy in this population. 
We describe a series of 5 HT recipients who began taking PCSK9i due to LDL-C > 100mg/dL despite 
ezetimibe therapy and, when tolerated, the highest dose of a statin, as recommended in the therapeutic 
positioning report published by the Ministry of Health, Consumer Affairs and Social Welfare of the 
Government of Spain. All patients were men, the mean age was 58.8±8 years, and the mean post-HT time 
was 13±5.2 years. In all patients, the immunosuppressant regimen included 3 drugs, and in 3 patients 
(patients 3, 4, and 5), the presence of GVD had been previously confirmed. Patients 1, 2, and 5 were 
receiving a combination of rosuvastatin 40mg/d and ezetimibe 10mg/d; patient 3 was receiving only 
ezetimibe 10mg/d due to a history of liver and muscle toxicity with several statins, and patient 4 was 
receiving a combination of pitavastatin 4mg/d and ezetimibe 10mg/d following muscular toxicity with 
other, more potent statins (Table 1). 
 
The PCSK9i administered to all patients was subcutaneous alirocumab 75mg/14d, for a mean of 15.6±6.5 
months. Mean baseline levels for total cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C), 
and triglycerides were 262±21, 155±19, 60±14, and 227±41mg/dL, respectively, and dropped to 150±33, 
61±23, 58±19, and 153±63mg/dL by the end of follow-up. All patients reached the target of LDL-C 
<100mg/dL, with percent reductions of 45% to 76% (Figure 1). 
 
There were no reports of drug-related specific adverse reactions, such as injection site reactions or 
pruritus, and no abnormalities were observed in the liver panel or in creatine kinase levels. None of the 
patients had unexplained fluctuations in blood concentrations of immunosuppressant drugs, episodes of 
graft rejection, or infections. Treatment was discontinued in only 1 patient, at the patient's own request 
(patient 2). Patient 3 experienced 2 acute non–Q-wave myocardial infarctions at 2 and 7 months after 
starting PCSK9i and an ischemic stroke at 12 months. The same patient had been hospitalized 3 years 
earlier due to unstable angina, and coronary angiography revealed GVD affecting 1 vessel, which was 
revascularized. Additionally, from the time the patient started alirocumab 75mg/14d, he had been taking 
only ezetimibe 10mg/d due to statin intolerance, with LDL-C levels> 100mg/dL persisting until the third 
cardiovascular event. At that time, pitavastatin 1mg/d was started; 4 months later, the patient reached the 
target of LDL-C <100mg/dL, experiencing good tolerance and no new adverse events. 
 
In summary, this is the first series in Spain of HT recipients treated with a PCSK9i. To date, only 2 
similar series have been published, one with 6 patients and a mean follow-up of 9 months5 and another 
with 10 patients and a mean follow-up of 10 months.6 Our series contributes further data with a longer 
follow-up (nearly 16 months). 
 
These results indicate the potential safety and efficacy of PCSK9i for treating hypercholesterolemia in HT 
recipients, although larger studies with longer follow-up are needed to confirm this hypothesis and to 
evaluate the effects in terms of cardiovascular morbidity and mortality. 
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Table 1. Baseline characteristics and trend in LDL-C levels in HT recipients receiving treatment with a PCSK9i agent (alirocumab 75mg/14d) 
Patient Age, y  
Time since HT, 
y  
IS regimen  Initial statin  Final statin  






         
1  68  9.1  TAC+EVL+corticosteroids  Rosuvastatin 40 mg/d  Rosuvastatin 20 mg/d  15  175  67  
2  48  9  CsA+MMF+corticosteroids  Rosuvastatin 40 mg/d  Rosuvastatin 40 mg/d  5.6  180  98  
3  58  10.5  TAC+EVL+corticosteroids  No  Pitavastatin 1 mg/d  21.4  129  69  
4  73  13.4  CsA+EVL+corticosteroids  Pitavastatin 4 mg/d  Pitavastatin 4 mg/d  23.6  146  35  
5  59  22.9  TAC+EVL+corticosteroids  Rosuvastatin 40 mg/d  Rosuvastatin 40 mg/d  12.3  146  38 
         
 
CsA, cyclosporin A; EVL, everolimus; HT, heart transplantation; IS, immunosuppression; LDL-C, low-density lipoprotein cholesterol; MMF, mycophenolate mofetil; PCSK9i: proprotein convertase subtilisin/kexin 




Figure 1. A, percent reduction in low-density lipoprotein cholesterol after the start of treatment with a proprotein convertase 
subtilisin/kexin type 9 inhibitor (PCSK9i) (alirocumab 75mg/14d). B-D, trend for creatine kinase (CPK), glutamic-pyruvic 
transaminase (GPT), and glutamic-oxalacetic transaminase (GOT) levels (baseline and end of follow-up) during PCSK9i therapy. 
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